Zoetis Inc. (NYSE:ZTS) today announced leadership changes that
will accelerate its long-term growth strategy in key markets and
add new talent to its executive team. Glenn David, Executive Vice
President and Chief Financial Officer (CFO) for Zoetis, has been
named Executive Vice President and Group President, overseeing
International Operations and other business units, effective June
1, 2021. In addition, the company announced Wetteny Joseph will
join Zoetis as Executive Vice President and Chief Financial
Officer, reporting to CEO Kristin Peck, and assume responsibility
for the oversight of the company’s financial management, planning,
and business development group, effective June 1, 2021.
“Glenn’s record of success at Zoetis, plus his deep knowledge of
our operations and the animal health industry, make him the ideal
leader to drive Zoetis’ next phase of global growth in
international markets, aquaculture, biodevices and pet insurance,”
said Chief Executive Officer Kristin Peck. “As CFO for the last
five years and a leader in animal health for a decade, Glenn has
been a champion for building our business. He has played a pivotal
role in supporting our recent product launches, scrutinizing new
business opportunities, and investing in global expansion
initiatives. We are very excited by the strong leadership qualities
and experience Glenn will bring to this role.”
“The Board and I are also excited to welcome Wetteny, a proven
leader in healthcare whose global experience and results-driven
approach will help ensure that Zoetis continues its strong growth
trajectory,” said Peck. “Wetteny has impeccable CFO credentials
from his years at Catalent, and he has built world-class Finance
organizations and strong relationships with the investment
community. I am confident that he will continue to enhance the
reputation Zoetis has built for our market performance, value
creation and leadership in animal health.”
As Group President, David will oversee Zoetis’ international
operations, including China and Brazil, two of the company’s
largest and fastest-growing markets. He will also be responsible
for the company’s aquaculture business (PHARMAQ), Global
BioDevices, and Pumpkin Pet Insurance.
“I am very proud of what we have accomplished at Zoetis over the
last eight years, and I see even greater opportunities ahead with
an innovative portfolio that is addressing critical needs and
defining new standards of care for animals,” said David. “I am
excited to take on a more customer-facing role leading our
commercial teams, and I look forward to helping accelerate our
long-term growth in international markets, where we see untapped
opportunities for our products and services.”
As CFO, Joseph will report directly to Chief Executive Officer
Kristin Peck and become part of the Zoetis Executive Team. He
brings with him valuable financial expertise and deep experience in
the healthcare industry from 13 years at Catalent, a global leader
in pharmaceuticals, biologics and consumer health products. During
his career, he has worked across diverse and complex businesses,
leading finance functions and business units, and managing
relationships with stakeholders from customers to investors.
“I am delighted with the tremendous opportunity to join a world
leading company like Zoetis,” said Joseph. “Zoetis has been
delivering sustainable revenue and earnings growth since its
launch, while also introducing innovative new products for
customers. I look forward to bringing my skills and experience to
Zoetis and building on that strong track record of performance with
Kristin and the team.”
About Glenn David
Since becoming CFO in 2016, David, age 49, has supported the
company’s ability to consistently grow revenue faster than the
market and grow adjusted net income faster than revenue. He has
supported the company’s investments in future growth through sound
business development and capital allocation strategies. He has
maintained a well-capitalized and financially disciplined business,
creating significant value for shareholders. Earlier in his career,
David served as Senior Vice President of Finance Operations for
Zoetis during its Initial Public Offering in 2013. Before the
Zoetis IPO, David served in various financial roles at Pfizer,
including Vice President of Global Finance for Pfizer Animal Health
and Vice President of Finance for the U.S. Primary Care
franchise.
About Wetteny Joseph
Joseph, age 49, has served as Senior Vice President and Chief
Financial Officer of Catalent since 2018. He joined Catalent in
2008 as Vice President and Corporate Controller and held various
senior finance roles until October 2015, when he was named
President, Clinical Supply Services, one of the company’s principal
business units. Before joining Catalent, Joseph held a variety of
senior financial positions at the industrial distribution company
HD Supply including CFO for its $1.2 billion plumbing and HVAC
business unit. He also served as Corporate Controller at Hughes
Supply, a Fortune 500, NYSE-listed company that was acquired by
Home Depot and became part of HD Supply. In his early career, Mr.
Joseph spent six years at PricewaterhouseCoopers as an auditor and
strategic financial advisor across a variety of industries.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After nearly 70 years innovating ways
to predict, prevent, detect, and treat animal illness, Zoetis
continues to stand by those raising and caring for animals
worldwide - from livestock farmers to veterinarians and pet owners.
The company’s leading portfolio and pipeline of medicines,
vaccines, diagnostics, and technologies make a difference in over
100 countries. In 2020, Zoetis generated revenue of $6.7 billion
with ~11,300 employees. For more, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of
Zoetis with respect to business plans or prospects and other future
events. These statements are not guarantees of future performance
or actions. Forward-looking statements are subject to risks and
uncertainties. If one or more of these risks or uncertainties
materialize, or if management's underlying assumptions prove to be
incorrect, actual results may differ materially from those
contemplated by a forward-looking statement. Forward-looking
statements speak only as of the date on which they are made. Zoetis
expressly disclaims any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of
risks, uncertainties and other matters can be found in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item
1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our
Current Reports on Form 8-K. Such risks and uncertainties may be
amplified by the COVID-19 pandemic and its potential impact on the
global economy and our business. These filings and subsequent
filings are available online at www.sec.gov, www.zoetis.com, or on
request from Zoetis.
ZTS-IR ZTS-COR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511005607/en/
Media Contacts: Bill Price
1-973-443-2742 (o) william.price@zoetis.com
Kristen Seely 1-973-443-2777 (o) kristen.seely@zoetis.com
Investor Contacts: Steve Frank
1-973-822-7141 (o) steve.frank@zoetis.com
Keith Gaub 1-973-822-7154 (o) keith.gaub@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Sep 2023 to Sep 2024